Resistance mechanism of bortezomib in multiple myeloma
10.3760/cma.j.issn.1009-9921.2017.05.017
- VernacularTitle:硼替佐米在多发性骨髓瘤中耐药机制的研究
- Author:
Xuehan MAO
- Keywords:
Multiple myeloma;
Drug resistance;
neoplasm;
Proteasome inhibitor;
Bortezomib
- From:
Journal of Leukemia & Lymphoma
2017;26(5):308-313
- CountryChina
- Language:Chinese
-
Abstract:
Bortezomib (BTZ), being the first proteasome inhibitor, has been applied widely in clinic. Through combining with targeting β5 subunit/chymotrypsin-like and inhibiting the activity of proteasome reversibly, BTZ manages to inhibit intracellular degradation of protein, thus inducing apoptosis of myeloma cells. Since 2000, when BTZ was approved by Food and Drug Administration (FDA) for treatment of multiple myeloma (MM), both response rates and long-term survival time of these patients have been improved significantly. However, most patients will inevitably end up with relapse or drug resistance due to its high heterogeneity. Thus, it is of great necessity to explore the mechanism as well as overcome BTZ resistance. This review aims to summarize the current researches available on mechanisms of BTZ resistance in MM.
